October 05, 2022
11 11 11 AM
Breaking News :
FireNews : Putin vows to ‘stabilise’ annexed regions as Ukraine makes gains #FireNews365 FireNews : The Aluu Four: Mob killing that shocked Nigeria. #FireNews365 FireNews : Stocks making the biggest moves midday: Tesla, Enphase Energy, Exxon Mobil and more #FireNews365 FireNews : Quartet heads skyward to join space station #FireNews365 FireNews : Ex-Google ad boss builds tracker-free search engine #FireNews365 FireNews : Uganda’s President Museveni sorry for son’s threat to invade Kenya #FireNews365 FireNews : High inflation has many Americans tweaking their holiday travel plans #FireNews365 FireNews : Ukraine joins Spain & Portugal 2030 World Cup bid #FireNews365 FireNews : Stocks making the biggest moves in the premarket: Tesla, Ford Motor, Goldman Sachs and more #FireNews365 FireNews : Iran protests: Schoolgirls heckle paramilitary speaker #FireNews365

FireNews : Stocks making the biggest moves premarket: Eli Lilly, Honeywell, Biogen and others #FireNews365

Check out the companies making headlines before the bell:

Eli Lilly (LLY) – The drugmaker beat estimates by 3 cents with adjusted quarterly earnings of $2.49 per share, while revenue beat forecasts as well. Results were boosted by a jump in sales of Lilly’s Trulicity diabetes drug and Covid-19 therapies. However, the stock slid 1.1% in the premarket.

Honeywell (HON) – Honeywell fell 3.4% in premarket trading after quarterly revenue missed estimates due to supply chain issues and other factors. Honeywell did beat estimates by a penny with an adjusted quarterly profit of $2.09 per share.

Biogen (BIIB) – Biogen fell 2.8% in premarket action after the drugmaker issued a lower than expected 2022 adjusted earnings forecast. Biogen expects sales of Alzheimer’s drug Aduhelm to be minimal following the government’s move to limit Medicare coverage of the drug. Biogen reported better-than-expected profit and revenue for the fourth quarter.

Merck (MRK) – Merck earned an adjusted $1.80 per share for the fourth quarter, beating the $1.53 consensus estimate. Revenue also topped Wall Street forecasts as its Covid-19 treatment molnupiravir helped to drive sales higher. Merck forecast adjusted 2022 earnings of $7.12 to $7.27 per share, below the consensus estimate of $7.29.

Cardinal Health (CAH) – The pharmaceutical distributor’s stock fell 2.1% in the premarket after it cut its full-year forecast due to inflation pressures and supply chain constraints. Cardinal Health beat estimates by 4 cents for its latest quarter, earning an adjusted $1.27 per share.

Meta Platforms (FB) – Meta Platforms plummeted 22.1% in premarket trading after missing bottom-line estimates for only the third time in the Facebook parent’s nearly ten-year history as a public company. It also issued a cautious outlook, pointing to factors such as a decline in user engagement and inflation taking a toll on advertiser spending.

T-Mobile US (TMUS) – T-Mobile earned 34 cents per share for its latest quarter, more than doubling the 15-cent consensus estimate, though the mobile service provider’s revenue fell short of analyst forecasts. T-Mobile also issued an upbeat forecast, and the stock soared 7.7% in the premarket.

Spotify (SPOT) – Spotify shares tumbled 9.6% in the premarket after the audio service issued a weaker-than-expected subscriber forecast. Spotify also reported a narrower-than-expected loss for its latest quarter and saw its revenue exceed estimates. The audio streaming service benefited from a jump in ad revenue, even amid the controversy surrounding its Joe Rogan podcast.

Align Technology (ALGN) – Align shares fell 2.6% in premarket trading after the maker of Invisalign dental braces said 2022 revenue would rise by 20% to 30% compared with the prior year’s growth of 60%. Align also beat top and bottom-line estimates for its latest quarter as volume sales for its aligners rose.

McKesson (MCK) – McKesson rallied 4.5% in the premarket after the pharmaceutical distributor reported better-than-expected top and bottom-line results. McKesson earned an adjusted $6.15 per share compared with a consensus estimate of $5.42, helped by the strength of its Covid-19 vaccine distribution business.


Source link